Actively Recruiting
Phase 1 Study of Oral SGR-1505 for Treatment of Mature B-Cell Cancers
Led by Schrödinger, Inc. · Updated on 2026-02-13
98
Participants Needed
36
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying SGR-1505, an oral MALT1 inhibitor, in adults with relapsed or refractory mature B-cell lymphomas. The study aims to evaluate the safety, tolerability, and pharmacological properties of SGR-1505 while determining the maximum tolerated or recommended dose. Exploratory groups will further assess early anti-tumor activity and safety, including combinations with other cancer drugs like BTK and BCL-2 inhibitors in specific B-cell cancers. Participants will receive SGR-1505 orally across up to nine different dose levels using two dosing schedules. Patients will be assigned to dose groups following an accelerated titration design that shifts to a traditional dose escalation method. The study is open-label and non-randomized, focusing on careful dose increases to find the optimal dosing for further research. During the study, participants will be closely monitored for adverse events, dose limiting toxicities, and treatment effects over up to two years. Researchers will track drug levels in the blood, tumor response rates, and disease control measures. Safety assessments, pharmacokinetics, and pharmacodynamics evaluations will occur throughout, with ongoing observation to understand the drugs impact and tolerability in this patient population.
CONDITIONS
Brief Title
Study of SGR-1505 in Mature B-Cell Neoplasms
Research Team
S
Study Physician
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here